Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
This review (2008) summarises the published research into hallucinogen-induced stimulus control in phenethylamine- and tryptamine-based hallucinogens, highlighting the receptors involved in their mechanism of action.
Abstract
Background
Although man’s first encounters with hallucinogens predate written history, it was not until the rise of the sister disciplines of organic chemistry and pharmacology in the nineteenth century that scientific studies became possible. Mescaline was the first to be isolated and its chemical structure determined. Since then, additional drugs have been recovered from their natural sources and synthetic chemists have contributed many more. Given their profound effects upon human behavior and the need for verbal communication to access many of these effects, some see humans as ideal subjects for study of hallucinogens. However, if we are to determine the mechanisms of action of these agents, establish hypotheses testable in human subjects, and explore the mechanistic links between hallucinogens and such apparently disparate topics as idiopathic psychosis, transcendental states, drug abuse, stress disorders, and cognitive dysfunction, studies in animals are essential. Stimulus control by hallucinogens has provided an intuitively attractive approach to the study of these agents in nonverbal species.
Objective
The intent of this review is to provide a brief account of events from the time of the first demonstration of hallucinogen-induced stimulus control to the present. In general, the review is limited to lysergic acid diethylamide (LSD) and the hallucinogenic derivatives of phenethylamine and tryptamine.
Results
The pharmacological basis for stimulus control by LSD and hallucinogenic phenethylamines and tryptamines is serotonergic in nature. The 5-HT2A receptor appears to be the primary site of action with significant modulation by other serotonergic sites including 5-HT2C and 5-HT1A receptors. Interactions with other neurotransmitters, especially glutamate and dopamine, are under active investigation. Most studies to date have been conducted in the rat but transgenic mice offer interesting possibilities.
Conclusions
Hallucinogen-induced stimulus control provides a unique behavioral tool for the prediction of subjective effects in man and for the elucidation of the pharmacological mechanisms of the action of these agents.
Research Summary of 'Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines'
Introduction
Winter frames the review by noting that, despite long-standing human use of hallucinogens, systematic scientific study of their mechanisms has relied heavily on animal models because many cardinal effects are subjective and not directly observable in nonverbal species. Stimulus control—training animals to report the interoceptive cue produced by a drug by choosing one response under drug and another under vehicle—has emerged as a practical behavioural approach for modelling hallucinogenic effects in animals and for testing pharmacological hypotheses about mechanism. This review is focused narrowly on lysergic acid diethylamide (LSD) and hallucinogenic derivatives of the phenethylamine and tryptamine classes. Winter sets out to trace the development of hallucinogen-induced stimulus control from its first demonstrations through to contemporary pharmacological interpretations, emphasising receptor-level mechanisms (particularly serotonergic sites) and the utility of drug discrimination to predict subjective effects in man and to dissect underlying neurochemistry.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- APA Citation
Winter, J. C. (2009). Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology, 203(2), 251-263. https://doi.org/10.1007/s00213-008-1356-8
References (4)
Papers cited by this study that are also in Blossom
Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Hoch, P. H., Cattell, J. P., Pennes, H. H. · American Journal of Psychiatry (1952)
Vollenweider, F. X., Gamma, A., Liechti, M. et al. · Neuropsychopharmacology (1998)
Cited By (15)
Papers in Blossom that reference this study
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Catalani, V., Corkery, J. M., Guirguis, A. et al. · European Neuropsychopharmacology (2021)
Zamberlan, F., Sanz, C., Pallavicini, C. et al. · Frontiers in Integrative Neuroscience (2018)
Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)
Davis, A. K., Barsuglia, J. P., Lancelotta, R. et al. · Journal of Psychopharmacology (2018)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Show all 15 papersShow fewer
Litjens, R. P. W., Brunt, T. M., Alderliefste, G. et al. · European Neuropsychopharmacology (2014)
Rolland, B., Jardri, R., Amad, A. et al. · BioMed Research International (2014)
Baggott, M. J., Siegrist, J. D., Galloway, G. P. et al. · PLOS ONE (2010)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.